MX2008011579A - Forma galenica divisible que permite una liberacion modificada del principio activo. - Google Patents

Forma galenica divisible que permite una liberacion modificada del principio activo.

Info

Publication number
MX2008011579A
MX2008011579A MX2008011579A MX2008011579A MX2008011579A MX 2008011579 A MX2008011579 A MX 2008011579A MX 2008011579 A MX2008011579 A MX 2008011579A MX 2008011579 A MX2008011579 A MX 2008011579A MX 2008011579 A MX2008011579 A MX 2008011579A
Authority
MX
Mexico
Prior art keywords
modified release
dosage form
active principle
tablet
form allowing
Prior art date
Application number
MX2008011579A
Other languages
English (en)
Inventor
Jean-Manuel Pean
Gilles Fonknechten
Patrick Genty
Patrick Wuthrich
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39796790&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2008011579(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of MX2008011579A publication Critical patent/MX2008011579A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una forma galénica divisible de liberación modificada de principio activo, donde la forma galénica no subdividida y una fracción de dicha forma obtenida por subdivisión tienen un perfil de disolución idéntico. Medicamentos.
MX2008011579A 2008-03-21 2008-09-10 Forma galenica divisible que permite una liberacion modificada del principio activo. MX2008011579A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0801561A FR2928836B1 (fr) 2008-03-21 2008-03-21 Forme galenique secable permettant une liberation modifiee du principe actif

Publications (1)

Publication Number Publication Date
MX2008011579A true MX2008011579A (es) 2009-09-21

Family

ID=39796790

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2008011579A MX2008011579A (es) 2008-03-21 2008-09-10 Forma galenica divisible que permite una liberacion modificada del principio activo.

Country Status (37)

Country Link
US (3) US20090238870A1 (es)
EP (2) EP2103302A1 (es)
JP (2) JP5231906B2 (es)
KR (3) KR20090101048A (es)
CN (1) CN101347414B (es)
AP (1) AP2729A (es)
AR (1) AR067993A1 (es)
AU (1) AU2008207680B8 (es)
BR (1) BRPI0803631A2 (es)
CA (1) CA2629670C (es)
CL (1) CL2008002486A1 (es)
CO (1) CO6020017A1 (es)
CR (2) CR10317A (es)
CU (1) CU23970B1 (es)
EA (1) EA200801862A1 (es)
EC (1) ECSP088727A (es)
FR (1) FR2928836B1 (es)
GT (1) GT200800163A (es)
HK (1) HK1127280A1 (es)
HN (1) HN2008001466A (es)
IL (1) IL193611A0 (es)
JO (1) JO3052B1 (es)
MA (1) MA31218B1 (es)
ME (1) ME01031B (es)
MX (1) MX2008011579A (es)
MY (1) MY150660A (es)
NI (1) NI200800256A (es)
NZ (1) NZ570715A (es)
PE (1) PE20090991A1 (es)
SA (1) SA08290555B1 (es)
SG (1) SG155819A1 (es)
SV (1) SV2008003023A (es)
TW (1) TWI396561B (es)
UA (1) UA86731C2 (es)
UY (1) UY31307A1 (es)
WO (1) WO2009125087A1 (es)
ZA (1) ZA200807354B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1931346T3 (da) 2005-09-09 2012-10-22 Angelini Labopharm Llc Trazodonsammensætning til indgivelse en gang om dagen
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
DE102010015123A1 (de) 2010-04-16 2011-10-20 Sanofi-Aventis Deutschland Gmbh Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TR201103946A1 (tr) 2011-04-22 2012-11-21 Sanovel İlaç Sanayi̇ Ve Ti̇caret Anoni̇m Şi̇rketi̇ Kontrollü salım sağlayan gliklazid formülasyonları.
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
CN106892856A (zh) * 2017-02-06 2017-06-27 山东科源制药股份有限公司 一种格列齐特粗品重结晶的制备方法
EP4121013A1 (en) 2020-03-16 2023-01-25 Grünenthal GmbH Scored tablet

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353887A (en) * 1979-08-16 1982-10-12 Ciba-Geigy Corporation Divisible tablet having controlled and delayed release of the active substance
CH648754A5 (en) * 1979-08-16 1985-04-15 Ciba Geigy Ag Pharmaceutical slow release tablet
US4851230A (en) * 1983-04-07 1989-07-25 Bristol-Myers Company Capsule shaped tablets
GB8724763D0 (en) * 1987-10-22 1987-11-25 Aps Research Ltd Sustained-release formulations
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
JPH069375A (ja) * 1992-04-10 1994-01-18 Takeda Chem Ind Ltd 分割可能な連結錠剤
DE4229085C2 (de) * 1992-09-01 1996-07-11 Boehringer Mannheim Gmbh Längliche, teilbare Tablette
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
CA2312990C (en) * 1997-12-08 2008-04-29 Bristol-Myers Squibb Company Novel salts of metformin and method
NZ506202A (en) * 1998-03-19 2003-10-31 Bristol Myers Squibb Co Biphasic controlled release delivery system for high solubility pharmaceuticals and method
SG70678A1 (en) * 1998-04-03 2000-02-22 Kyowa Hakko Kogyo Kk Dividable tablet and press-through pack
JP2006052230A (ja) * 1998-04-03 2006-02-23 Kyowa Hakko Kogyo Co Ltd 分割錠剤及びプレススルーパック
AP1243A (en) * 1999-02-01 2004-02-02 Servier Lab Core tablet for controlled release of gliclazide after oral administration.
EA200401009A1 (ru) * 1999-03-31 2004-12-30 Янссен Фармацевтика Н.В. Предварительно желатинированный крахмал в композиции с контролируемым высвобождением
US6878749B2 (en) * 1999-09-17 2005-04-12 Novartis Ag Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes
DE10117208A1 (de) * 2001-04-06 2002-10-10 Wolff Walsrode Ag Verfahren zur Herstellung von niederviskosen, wässrigen Celluloseetherlösungen
CN1294908C (zh) * 2003-06-08 2007-01-17 安徽省医药科技实业公司 口服格列齐特缓释制剂
AU2004318976B2 (en) * 2004-04-29 2009-04-09 Lotus Pharmaceutical Co., Ltd. Oral modified-release lozenges and their preparation method
US7622137B2 (en) * 2004-05-21 2009-11-24 Accu-Break Technologies, Inc. Dosage forms contained within a capsule or sachet
WO2006061697A1 (en) * 2004-12-06 2006-06-15 Themis Laboratories Private Limited Sulfonylurea compositions and a process for its preparation
DE102005014141B4 (de) * 2005-03-23 2006-12-21 Hennig Arzneimittel Gmbh & Co. Kg Tablettenförmige Retardzubereitung gegen Schwindel
US20060280790A1 (en) * 2005-04-08 2006-12-14 Ju Tzuchi R Pharmaceutical formulations
KR20080034517A (ko) * 2005-08-18 2008-04-21 데이진 화-마 가부시키가이샤 정확한 용량 분할 기능을 갖는 제제
JP5046501B2 (ja) * 2005-08-18 2012-10-10 帝人ファーマ株式会社 複数の薬物を分離して保持する錠剤
DK1931346T3 (da) * 2005-09-09 2012-10-22 Angelini Labopharm Llc Trazodonsammensætning til indgivelse en gang om dagen
JOP20180109A1 (ar) * 2005-09-29 2019-01-30 Novartis Ag تركيبة جديدة
MX2009001429A (es) * 2006-08-10 2009-02-17 Takeda Pharmaceutical Composicion farmaceutica.
WO2008062470A2 (en) * 2006-10-19 2008-05-29 Torrent Pharmaceuticals Limited Stabilized controlled release dosage form of gliclazide
JP2008208078A (ja) * 2007-02-27 2008-09-11 Takada Seiyaku Kk 分割錠剤

Also Published As

Publication number Publication date
JP5231906B2 (ja) 2013-07-10
EP3025706A1 (fr) 2016-06-01
FR2928836A1 (fr) 2009-09-25
GT200800163A (es) 2010-05-21
ECSP088727A (es) 2008-10-31
NI200800256A (es) 2010-02-11
KR20110112266A (ko) 2011-10-12
HK1127280A1 (en) 2009-09-25
NZ570715A (en) 2010-10-29
FR2928836B1 (fr) 2011-08-26
CL2008002486A1 (es) 2008-12-26
TWI396561B (zh) 2013-05-21
ME01031B (me) 2012-10-20
AR067993A1 (es) 2009-10-28
AU2008207680A1 (en) 2009-10-08
US20090238870A1 (en) 2009-09-24
PE20090991A1 (es) 2009-07-18
KR20150035829A (ko) 2015-04-07
MY150660A (en) 2014-02-14
AP2729A (en) 2013-08-31
CN101347414A (zh) 2009-01-21
AP2008004614A0 (en) 2008-10-31
SA08290555B1 (ar) 2011-07-20
KR101693189B1 (ko) 2017-01-05
UA86731C2 (ru) 2009-05-12
US20130295176A1 (en) 2013-11-07
CR20140334A (es) 2014-08-20
SG155819A1 (en) 2009-10-29
IL193611A0 (en) 2009-08-03
AU2008207680B2 (en) 2010-04-22
EP2103302A1 (fr) 2009-09-23
CR10317A (es) 2008-11-26
JP2009227651A (ja) 2009-10-08
EA200801862A1 (ru) 2009-10-30
CN101347414B (zh) 2011-11-23
UY31307A1 (es) 2008-10-31
MA31218B1 (fr) 2010-03-01
BRPI0803631A2 (pt) 2011-03-29
KR20090101048A (ko) 2009-09-24
AU2008207680B8 (en) 2010-05-13
SV2008003023A (es) 2010-07-29
JO3052B1 (ar) 2017-03-15
ZA200807354B (en) 2008-11-26
US20140221449A1 (en) 2014-08-07
JP2010209103A (ja) 2010-09-24
CU20080179A7 (es) 2011-04-26
CA2629670C (fr) 2012-04-17
CO6020017A1 (es) 2009-03-31
CU23970B1 (es) 2013-12-27
WO2009125087A1 (fr) 2009-10-15
TW200940109A (en) 2009-10-01
HN2008001466A (es) 2011-04-25
CA2629670A1 (fr) 2008-10-01

Similar Documents

Publication Publication Date Title
MX2008011579A (es) Forma galenica divisible que permite una liberacion modificada del principio activo.
CR11709A (es) Preparacion solida de desintegracion oral
MX2013014788A (es) Liberacion modificada de 4-metil-3-[[4-(3-piridinl)-2-pirimidinil] -amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluoro-metil)-fenil ]-benzamida solubilizada utilizando acidos organicos.
ECSP10010489A (es) Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación
TN2013000216A1 (en) Crystalline forms of 5-chloro-n2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-n4[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2,4-diamine
MX341200B (es) Composicion farmaceutica de disolucion rapida.
NI201100227A (es) Composiciones de dosis fija farmacéuticas sólidas que comprenden irbesartán y amlodipina, su preparación y su aplicación terapéutica.
MX340188B (es) Elaboracion de granulos sin activos y tabletas que comprenden los mismos.
TN2015000135A1 (en) Modified release formulations for oprozomib
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
NZ603199A (en) Orally disintegrating tablet containing acarbose
WO2011037976A3 (en) Pramipexole pharmaceutical formulations
JO3112B1 (ar) تركيبة دوائية سريعة التحلل
CO6592109A2 (es) Nueva forma cristalina de un derivado de ciclopropilbenzamida
SI1994926T1 (sl) Farmacevtske oblike valsartana
WO2011141791A3 (en) Extended release formulations of desvenlafaxine base
UA105285C2 (uk) Тверда фармацевтична композиція раміприлу і безилату амлодипіну і її отримання
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
CL2016000183A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido redispersable que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
EA201170843A1 (ru) Предварительно спрессованные быстро распадающиеся лекарственные формы соединений с низкой пероральной биодоступностью
MX2012002209A (es) Formulaciones de liberacion controlada de compuestos de anabaseina y usos de los mismos.
WO2011107921A3 (en) Modified release composition of milnacipran
CL2016000182A1 (es) Composición farmacéutica anti-tuberculosis estable en una forma de un comprimido recubierto que comprende gránulos de isoniazid y gránulos de rifapentina y su proceso de preparación
BR112013000870A2 (pt) forma de dosagem farmacêutica oral em comprimidos
TR200805337A2 (tr) Valsartan etkin maddesini içeren yeni oral farmasötik formülasyonlar

Legal Events

Date Code Title Description
FG Grant or registration